JP2006508994A5 - - Google Patents

Download PDF

Info

Publication number
JP2006508994A5
JP2006508994A5 JP2004554480A JP2004554480A JP2006508994A5 JP 2006508994 A5 JP2006508994 A5 JP 2006508994A5 JP 2004554480 A JP2004554480 A JP 2004554480A JP 2004554480 A JP2004554480 A JP 2004554480A JP 2006508994 A5 JP2006508994 A5 JP 2006508994A5
Authority
JP
Japan
Prior art keywords
formoterol
roflumilast
pharmaceutical
daily dose
lung disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004554480A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006508994A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/013275 external-priority patent/WO2004047829A1/en
Publication of JP2006508994A publication Critical patent/JP2006508994A/ja
Publication of JP2006508994A5 publication Critical patent/JP2006508994A5/ja
Pending legal-status Critical Current

Links

JP2004554480A 2002-11-27 2003-11-26 ロフルミラスト及びホルモテロールを含有する新規の相乗組合せ Pending JP2006508994A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02026505 2002-11-27
PCT/EP2003/013275 WO2004047829A1 (en) 2002-11-27 2003-11-26 New synergistic combination comprising roflumilast and formoterol

Publications (2)

Publication Number Publication Date
JP2006508994A JP2006508994A (ja) 2006-03-16
JP2006508994A5 true JP2006508994A5 (enExample) 2006-11-30

Family

ID=32338002

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004554480A Pending JP2006508994A (ja) 2002-11-27 2003-11-26 ロフルミラスト及びホルモテロールを含有する新規の相乗組合せ

Country Status (31)

Country Link
US (1) US20060142308A1 (enExample)
EP (1) EP1567139B1 (enExample)
JP (1) JP2006508994A (enExample)
KR (1) KR101071798B1 (enExample)
CN (1) CN100346777C (enExample)
AT (1) ATE399543T1 (enExample)
AU (1) AU2003292120B2 (enExample)
BR (1) BR0316451A (enExample)
CA (1) CA2506962C (enExample)
CO (1) CO5690570A2 (enExample)
CY (1) CY1110369T1 (enExample)
DE (1) DE60321953D1 (enExample)
DK (1) DK1567139T3 (enExample)
EA (1) EA009935B1 (enExample)
ES (1) ES2309357T3 (enExample)
HR (1) HRP20050579B1 (enExample)
IL (1) IL168308A (enExample)
IS (1) IS2575B (enExample)
MA (1) MA27539A1 (enExample)
ME (1) ME00489B (enExample)
MX (1) MXPA05005437A (enExample)
NO (1) NO334247B1 (enExample)
NZ (1) NZ540659A (enExample)
PL (1) PL216752B1 (enExample)
PT (1) PT1567139E (enExample)
RS (1) RS51081B (enExample)
SI (1) SI1567139T1 (enExample)
TN (1) TNSN05131A1 (enExample)
UA (1) UA83018C2 (enExample)
WO (1) WO2004047829A1 (enExample)
ZA (1) ZA200503308B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
DK1606261T3 (da) 2003-03-10 2010-01-18 Nycomed Gmbh Hidtil ukendt fremgangsmåde til fremstilling af roflumilast
AU2006224619B2 (en) * 2005-03-16 2012-06-07 Takeda Gmbh Taste masked dosage form containing roflumilast
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
ES2378281T3 (es) * 2006-07-05 2012-04-10 Nycomed Gmbh Combinación de atorvastatina con un inhibidor de fosfodiesterasa 4 para el tratamiento de neumopatías inflamatorias
WO2013077830A1 (en) * 2011-11-25 2013-05-30 Mahmut Bilgic Synergistilly active combinations of roflumilast and carmoterol
US20130172303A1 (en) * 2012-01-03 2013-07-04 Forest Laboratories Holdings Ltd. Roflumilast compositions for the treatment of copd
LT2948148T (lt) * 2013-01-28 2020-12-28 Incozen Therapeutics Pvt. Ltd. Autoimuninių, kvėpavimo ir uždegiminių sutrikimų gydymo būdai, įkvėpiant roflumilasto n-oksidą
CN104800214A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入气雾剂复方及制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
DE59410119D1 (de) * 1993-07-02 2002-06-20 Byk Gulden Lomberg Chem Fab Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
DE69835594T2 (de) * 1997-02-17 2007-08-16 Altana Pharma Ag Zusammensetzungen zur behandlung von irds oder ards die 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy) benzamid und lungensurfactant enthalten
DK0975347T3 (da) * 1997-02-28 2008-06-16 Nycomed Gmbh Synergistisk kombination af PDE-inhibitorer og adenylatcyclase-agonister eller guanylcyclyseagonister
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
CZ293735B6 (cs) * 1998-08-26 2004-07-14 Smithkline Beecham Corporation Farmaceutický prostředek pro léčbu plicní nemoci
US6303145B2 (en) * 1999-05-10 2001-10-16 Sepracor Inc. (S,R) formoterol methods and compositions
CA2715683A1 (en) * 1999-08-21 2001-03-01 Nycomed Gmbh Synergistic combination
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
WO2002076933A1 (en) * 2001-03-22 2002-10-03 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
WO2002088167A1 (en) * 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha

Similar Documents

Publication Publication Date Title
US6790465B2 (en) Composition and method for treating snoring
JP2023041862A5 (enExample)
JP2022180461A5 (enExample)
JP2003292443A5 (enExample)
NZ585856A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
JP6762931B2 (ja) 経鼻組成物と該経鼻組成物の使用方法の改善
MX2009009131A (es) Mejoras en y con relacion a composiciones medicinales.
JP2009269923A5 (enExample)
NZ585857A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
JP2007520506A5 (enExample)
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
JP2002528502A5 (enExample)
JP2003206238A (ja) 医薬組成物
JP2005508963A5 (enExample)
WO2005041921A3 (en) Dry powder compositions for inhalation therapy comprising calcium stearate, medical devices therefor
CA2519175A1 (en) A method of treating a systemic disease
JP2004537500A5 (enExample)
EP1393734A4 (en) DRUG AGAINST DARMER DISEASES
GB2430623A (en) Medicaments for treating chronic respiratory disease
JP2013536837A5 (enExample)
JP2016505050A5 (enExample)
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
JP2011500589A5 (enExample)
JP2002540148A5 (enExample)
CA2506962A1 (en) Synergistic combination comprising roflumilast and formoterol